Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tanespimycin 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chondrosarcoma × alanosine × Clear all
NCT00062283 2013-06-26

Alanosine in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡